The Supreme Court said it will hear arguments on March 26 about how patients can access the commonly used abortion pill, mifepristone.
Judge Matthew Kacsmaryk
Supreme Court to Take Case on Abortion Pill Availability
The Supreme Court agreed Dec. 13 to look at a dispute over the availability of a commonly used abortion pill, mifepristone, making it the first abortion case it will hear since its decision overturning Roe v. Wade last year.
FDA Faces Skeptical Questioning From Federal Judges Over Abortion Pill
In a two-hour hearing on May 17 looking at the U.S. Food and Drug Administration’s decades-old approval of an abortion pill, federal judges seemed to have a harsher line of questioning for attorneys for the federal government and the drug maker, indicating they might be sympathetic to those challenging the drug’s availability.
Appeals Court Hears Abortion Pill Case, Next Stop Supreme Court
A federal appeals court in Louisiana is hearing arguments May 17 about the accessibility of the abortion drug mifepristone.
Supreme Court Extends Administrative Stay in Abortion Pill Legal Challenge
The U.S. Supreme Court said it would extend the administrative stay in the abortion pill dispute until April 21, temporarily keeping in place status quo federal regulations regarding the use of an abortion drug, and giving the court additional time to consider a lower court’s ruling to stay the U.S. Food and Drug Administration’s approval of the drug.
Supreme Court Temporarily Blocks Lower Court Rulings Restricting Abortion Pills Amid Legal Challenge
The U.S. Supreme Court said April 14 it would temporarily keep in place status quo federal regulations regarding the use of an abortion drug, giving the court additional time to consider a lower court’s ruling to stay the U.S. Food and Drug Administration’s approval of the drug.
Federal Judges Issue Conflicting Rulings on FDA’s Approval of Abortion Pill
Two very different rulings on April 7 by federal judges on the abortion drug mifepristone highlight the country’s disparate views on the subject and signal that the Supreme Court will likely have to weigh in on the drugs’ future availability.
